Immunotherapy duo aims to shrink colon tumors before surgery
NCT ID NCT07224022
First seen Nov 03, 2025 · Last updated Apr 28, 2026 · Updated 31 times
Summary
This study tests whether two immunotherapy drugs, cemiplimab and fianlimab, can safely shrink colon tumors before surgery in people with stage II-III colon cancer that hasn't spread. Participants get two IV doses, then surgery, and are followed for up to three years. The goal is to see if this approach is feasible and safe, and to measure how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.